Communiqués Merck & Co., Inc.

Actions

MRK

US58933Y1055

Temps réel estimé Cboe BZX Autres places de cotation 18:49:50 10/06/2024			Varia. 5j.	Varia. 1 janv.
130,2 ^USD	-0,34 %		+1,34 %	+19,37 %

05/06	MERCK & CO., INC. : HSBC conserve son opinion neutre	ZM
04/06	Transcript : Merck & Co., Inc. Presents at 2024 American Society of Clinical Oncology Annual Meeting, Jun-03-2024 06:00 PM

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	05/06	BU
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors	04/06	AQ
Anaveon announces IND approval of ANV600-001 Phase I/II clinical study	30/05	AQ
FDA Grants Priority Review to Merck's Application for KEYTRUDA plus Chemotherapy as First-Line Treatment of Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma	30/05	AQ
Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival Endpoint in Patients with High-Risk Early-Stage Triple Negative Breast Cancer	29/05	AQ
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024	29/05	AQ
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma	29/05	BU
Merck to Acquire EyeBio	29/05	BU
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results	29/05	AQ
Merck Announces Third-Quarter 2024 Dividend	28/05	BU
Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)	28/05	BU
BioInvent Presents Promising Clinical Efficacy and Safety for anti-TNFR2 agent BI-1808 at ASCO 2024	23/05	AQ
BioInvent Presents Promising Phase 1 Data for BI-1206 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors at ASCO 2024	23/05	AQ
MSD collaboration to drive development of solid tumour combination therapy	21/05	AQ
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation	21/05	AQ
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline	15/05	BU
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer	14/05	AQ
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma	13/05	BU
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA plus Chemotherapy, With or Without Radiotherapy, for Patients with Newly Diagnosed, High-Risk Endometrial Cancer	10/05	AQ
Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy	09/05	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Merck & Co., Inc. : Une vache à lait qui cache des vedettes

Le 11 juillet 2022 à 11:12